Chris Mehlin

Chris Mehlin

Company: Fred Hutchinson Cancer Research Center

Job title: Director, Protein Therapeutics


Dr. Mehlin has been employed for over two decades in the development of both small and large molecule therapeutics.  He is a named inventor on over eighteen therapeutic antibody patents, including two that have been approved by the FDA (Repatha, Siliq).  He has held a variety of positions in biotech, pharma, and academia, and he is currently leading efforts at the Fred Hutchinson Cancer Research Center to develop paired bispecific antibodies for the treatment of cancer.


© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.